Patent · US Active

5-hydroxyalkylbenzimidazoles as mIDH1 inhibitors

US10414734B2 · kind B2 · utility

1Cited by

5References

16Claims

0Family size

Assignee

Bayer Pharma Aktiengesellschaft · DE

Inventors

Olaf Panknin · Berlin, DE
Sven Ring · Jena, DE
Katja Zimmermann · Mülheim an der Ruhr, DE
Roland Neuhaus · Berlin, DE

Key dates

Filing date	Jul 12, 2016
Grant date	Sep 17, 2019
Priority date	—
Expiry date	Jul 12, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to benzimidazol-2-amines of general formula (I) in which R1, R2, R3, R4, R5, R6 and R7 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.